<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02621125</url>
  </required_header>
  <id_info>
    <org_study_id>Fertilix</org_study_id>
    <nct_id>NCT02621125</nct_id>
  </id_info>
  <brief_title>Fertilix Supplements and Assisted Reproductive Technology</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Reproductive Associates</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CellOxess LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Reproductive Associates</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a double blind, randomized, placebo controlled clinical trial to test the efficacy of
      the antioxidant formulation Fertilix® in lowering the levels of damaged sperm DNA in men
      diagnosed with moderate to high Sperm Oxidative DNA Damage (SODD)
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date type="Actual">February 2016</start_date>
  <completion_date type="Actual">February 2016</completion_date>
  <primary_completion_date type="Actual">February 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction in sperm DNA damage</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Spermatozoa</condition>
  <arm_group>
    <arm_group_label>Fertilix</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fertilix supplementation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Fertilix</intervention_name>
    <description>daily supplementation</description>
    <arm_group_label>Fertilix</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males with a sperm sample containing 8-OHdG levels &gt; 15% and must be capable of
             producing an ejaculate containing &gt;10million sperm upon study enrollment.

          -  Male is between 20-55 years of age seeking treatment for infertility with his partner
             at URA and who is a candidate for an IUI, IVF or IVF-ICSI (excluding donor egg)
             procedure.

          -  Female is between 20-42 years of age

          -  Female exhibits tubal patency on hydrosonogram or hysterosalpingogram (HSG)

          -  Female exhibits normal uterine cavity by hysteroscopy, hydrosonogram or
             hysterosalpingogram (HSG).

        Exclusion Criteria

          -  Subjects with initial semen analysis of an ejaculate containing &lt; 10 million sperm.

          -  Men who have been taking nutraceuticals, vitamins or other compounds known to have
             antioxidant activities within4 weeks of the study. No other supplements may be taken
             with Fertilix.

          -  Men who have hypersensitivity or an allergy to any of the ingredients in Fertilix®.

          -  Men who have been treated with a chemotherapeutic agent known to cause sterility, such
             as cyclophosphamide.

          -  Men who have taking anabolic steroids or testosterone replacement within 4 months of
             the study.

          -  Men currently being treated with a Ca++ channel blocker or other medical treatment
             known to adversely affect sperm production or function.

          -  Men with HIV, hepatitis B and C.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University Reproductive Associates</name>
      <address>
        <city>Hasbrouck Heights</city>
        <state>New Jersey</state>
        <zip>07604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 1, 2015</study_first_submitted>
  <study_first_submitted_qc>December 1, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 3, 2015</study_first_posted>
  <last_update_submitted>May 1, 2017</last_update_submitted>
  <last_update_submitted_qc>May 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Reproductive Associates</investigator_affiliation>
    <investigator_full_name>Peter McGovern, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

